Closed manufacturing of cell therapies is widely accepted as an effective way to create a safer therapeutic product through reduction of error often associated with traditional manual cell processing techniques. In addition to closing manufacturing systems, the industry is moving toward targeted gene delivery methods such as transfection with CRISPR-Cas9 to achieve both performance and safety enhancements over traditional random integration of vectors [1].
Thermo Fisher Scientific is developing a family of highly flexible and modular instruments that can be digitally and physically connected to create a closed, end-to-end cell therapy manufacturing platform. Here, we introduce the Gibco™ CTS™ Xenon™ Electroporation System and highlight its ability to transform your current transfection step into one that’s closed, optimized, and scalable. To demonstrate a transition from research and discovery to process development and manufacturing, we compare the CTS Xenon system to the Invitrogen™ Neon™ Transfection System, a small-scale, benchtop device that is suitable for research and early process development.
